Aromatase inhibitors (AIs)-specifically, letrozole, anastrozole and exemestane-represent the current gold standard for patients with estrogen-receptor-positive breast cancer (ER + BC).
First-pass extracted concept
aromatase inhibitors
Candidate: concept label2 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
AIs, anastrozole, exemestane, letrozole
Evidence Snippets
In the United States, the Food and Drug Administration (FDA) has approved endocrine therapies for ER-positive breast cancers that include ... aromatase inhibitors (AIs).
Supporting Sources
Linked Claims
Soy, cow's milk, sesame seeds, and sesame oil may have estrogen-like effects that could diminish the anti-estrogenic efficacy of aromatase inhibitors.
ER-positive breast cancers are the most common molecular subtype of breast cancer and comprise about 70% of breast carcinoma diagnoses worldwide.
FDA-approved endocrine therapy classes for ER-positive breast cancer include SERMs, SERDs, and aromatase inhibitors.
Letrozole, anastrozole, and exemestane are described as the current gold standard aromatase inhibitors for estrogen-receptor-positive breast cancer patients.
Endocrine therapy is the foremost strategy for treatment of ER-positive breast cancer.